Introduction
evidence that such practices exist. The medical director's duties for which he/she is compensated in many Over the past decade, the delivery of medical care has units are unclear. undergone dramatic changes and the practice of nephrologists in their care of end-stage renal disease ( ESRD) patients has been transformed. In the US, Physician's responsibility for patient outcome approximately 70% of patients are now dialysed in facilities managed and owned by corporate entities.
There are few data that deal with the outcome of These companies are publicly traded on the stock patients in corporate-run dialysis units versus nonexchanges and thus have investor-owners. Some of profit health care providers. However, a recent publicathese companies are vertically integrated, such that tion in a peer-reviewed journal suggested that mortality everything that is purchased such as dialysis machines, was greater in these corporate units [1] . While there dialysers, accessories and tubing are products of the has been bitter criticism of these findings by industry corporation. The dialysis nurses are employees of the representatives [2], the fact remains that data using corporation. While physicians managing their patients the United States Renal Data System database raise in these units are usually not corporation employees questions as to the physician's role and responsibility some exceptions exist. It is unclear whether these trends for these outcomes. A further disturbing trend was affect the outcomes of nephrology care, but at the very that the 'for-profit' dialysis units also have lower least they make the relationship between the doctors referral rates for transplantation than non-profit units and their patients more complex. Decisions regarding [1] . While there are many explanations for this it is drugs and medical interventions including the adminishard to avoid the conclusion that one possibility is tration of erythropoietin are often dictated by corporthat loss of patients from these units results in loss ate policy rather than individual patient needs. As an of revenue. example, most experts agree that erythropoietin given subcutaneously is equally effective as given intravenously, and is certainly cheaper. Yet intravenous Differences in dialysis practice between countries erythropoietin yields dialysis units and their proprietors maximum profit based on current reimbursement polThe nephrology profession is increasingly subject to icies. Since it is often not the patient that pays for questions about its ethics and behaviour. Physician their drugs, the accountability for these practices is left visits to dialysis centres in the US are relatively infreto third parties such as insurers and the government. quent compared to those of other countries. It is Peculiarly, erythropoietin prices are not negotiated by unclear if this factor results in adverse outcomes in the major payers but instead with providers. Other mortality, morbidity and hospitalizations. Home diacost saving manoeuvers by corporations have been lysis rates are much higher in Canada, Australia and decreases in nursing staff, and decreases in other amenNew Zealand than in the US with equal or better ities afforded the dialysis patient, such as meals and mortality statistics. These differences in practice are transportation services as well as dialysis schedules not simply explained by demographics, but probably that are often inconvenient for patients. To make these reflect the influence of corporate dialysis and capitated changes even more complex, individual physicians, in reimbursement procedures in the US. addition to their patient responsibilities, often serve in a capacity as medical director of these corporateoperated dialysis units for which they receive a specific Medical decision making: potential conflicts of fee. In academic centres, these payments often go to interest divisions or departments to help cover other expenses. While it is against the current laws in the US to compensate these physician-directors based on number This is not to say that corporate involvement is bad but it does raise questions about the responsibility of Correspondence and offprint requests to: William M. Bennett, MD, physicians to their patients as opposed to their loyalty FACP, Solid Organ and Cellular Transplantation, Legacy Good to corporate entities, and raises the spectre of medical Samaritan Hospital, 1040 NW 22nd Avenue, Suite 540, Portland, OR 97210, USA.
decisions being made for non-medical reasons. While the possibility of ethical conflicts does not mean that data, proprietary needs and prior approval for publication all may be negative incentives to present data as ethical conflicts necessarily exist, it is in my view in the best interest of the profession to be completely they are developed especially if they are contrary to the sponsor's goals and bottom line. transparent about their relationships with industry, both to the major payer, usually the government, and to the patients they serve. One rule of thumb would Transparency of physicians' relationship with be the old adage that says that any relationship you industry would not want publicized in the newspaper is probably not one you should be engaging in. Professional nephProfessional education is also heavily subsidized by rology societies can play a role here: understanding industry and while there are established guidelines for the current practices of their members by obtaining relationships between sponsors and educational activitdata and setting professional standards.
ies, the guidelines have become increasingly blurred with frequent incomplete disclosure of direct and indir-
Performance measures versus doctor-patient
ect perquisites for speakers and the use of other relationship incentives such as resort travel to deliver the sponsor's messages to physicians. There are disturbing data that marketing influences physician behaviour whether or The trust between a physician and his patient is in my not physicians like to think so [3] . Marketing budgets view a sacred one and if eroded leads to cynicism and of companies would tend to confirm this. impacts the major role of the physician which is to be the patient's advocate. Societal goals and group outcomes based on performance measures such as average From a sound cooperation with industry to optimal Kt/V, serum albumin and average haematocrit are fine patient care but they can mask inadequacies in the delivery of individual patient care under the guise of quality Obviously, complete disconnection between nephrologimprovement. Medical care is much more complex ists and industry would result in little industry involvethan these surrogate markers can possibly reveal with ment in nephrology innovation, research or education. the doctor-patient relationship being the most difficult
In some countries where there are governmentfactor to measure. mandated policies, this trend already exists resulting in markedly reduced choices in prescribing. In New
Patient care: an alternative to profit or institutional Zealand, for example, erythropoietin is not given to any patient pre-dialysis because of cost considerations.
programmes?
Also, relatively few patients are placed on centre haemodialysis because of the expense, and acceptance The market economy is here to stay in the western for any haemodialysis care is limited for those indiworld and this is probably a good thing in terms of viduals in whom home dialysis is not feasible. products and services available to patients. However, Rehabilitation potential is felt to be a major selection the nephrology profession should not compromise or criterion for acceptance for ESRD care although these subjugate its ideals and practices to the needs of predictions are seldom precise enough to use in specific corporate shareholders or profits. Non-profit dialysis cases to deny treatment. Thus, somewhere between units also should be open to similar scrutiny because these two extremes, the nephrology profession must while their profits do not go to anonymous sharetry to maintain its ideals and the primacy of the holders they often disappear into an abyss and are doctor-patient relationship. We should demand transused to cover administrative and bureaucratic needs parency and honesty in all of our relationships with rather than benefiting patients. Many academic medindustry so that hopefully in the future nephrologists ical centres use revenues generated by their dialysis will not be just corporate employees without any populations to offset money losing programmes in the autonomy to provide care for individual patients who institution rather than putting the money back to need help. These issues are obviously difficult and it improve patient care or even nephrology activities.
seems to me that each nephrologist needs to look at their own practice and relationships and ask whether or not these relationships stand up to outside scrutiny.
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